Factor VIII Intron 22 Inversion in Severe Hemophilia A Patients in Palestine

Table 3

Severe HA patients’ studied characteristics with regard to age, age at first exposure to FVIII concentrates, exposure days, family history of inhibitors, and inhibitors production with respect to Inv22.

Studied characteristics	Severe HA cases (N = 30)
	Positive for inhibitors (N = 14)	Negative for inhibitors (N = 16)
Mean age (years) ± SD, range	14 ± 6, 4–27	24 ± 7, 6–48
Age at first exposure to FVIII (N %)
<6 months	7 (50%)	6 (37.5%)
≥6 months	7 (50%)	10 (62.5%)
Mean in months ± SD	16 ± 12	29 ± 38
Exposure days (N %)
<120	14 (100%)	5 (31.3)
≥120	0 (0%)	11 (68.7%)
Mean days of exposure ± SD	64 ± 21	152 ± 73
Range	6–120	28–377
Family history of inhibitors (N %)	13 (92.9%)	3 (11.5%)
Inv22 mutation with inhibitors (N %)
Positive for Inv22	5 (45.5%)	6 (54.5%)
Negative for Inv22	9 (47.4%)	10 (52.6%)
Total	14 (46.7%)	16 (53.3%)

SD: standard deviation.